Observational studyBMC nephrology2025
Glycolytic control proteins in urinary extracellular vesicles are elevated during kidney transplant T cell-mediated rejection.
Observational study in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Orchestrating glucose metabolism: PFKFB2 as a signal-integrating conductor in homeostasis and disease.The Journal of biological chemistry · 2026Review
- Secretion of Extracellular Vesicles Into the Mesenteric Lymph During Fasting and Lipid Absorption.Journal of extracellular biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA priority in kidney transplant management is the ability to monitor allograft health accurately, frequently and less-invasively. Metabolic reprogramming from fatty acid oxidation to glycolysis has been associated with kidney injury. Given the histological localisation of T cell-mediated rejection (TCMR) to the tubulointerstitium, we hypothesised that expression of glycolytic control proteins contained in urinary extracellular vesicles (UEV) may increase during TCMR.
methodsIn this prospective observational study, urine samples were collected from kidney transplant recipients prior to indication biopsy. UEV were separated by differential ultracentrifugation. Vesicle markers, glycolytic control proteins and CD3 were assayed by immunoblotting. Differences in protein detection were compared across biopsy diagnoses (TCMR versus not) and Banff lesion scores.
results51 paired urine and biopsy samples from 43 subjects were included. The TCMR group comprised of 6 cases of TCMR and 1 borderline TCMR. The remaining 44 samples comprised a "No TCMR" group. There was significant increase in phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 (PFKFB4) (p = 0.018) in TCMR compared to No TCMR, and similarly when tubulitis (p = 0.037) and interstitial inflammation (p = 0.047) were present. Total inflammation score ≥ 1 was associated with increases in PFKFB2 (p = 0.027), PFKFB3 (p = 0.090) and PFKFB4 (p = 0.0098). Interstitial fibrosis was associated with increased PFKFB2 (p = 0.0045) and PFKFB3 (p = 0.045). CD3 + UEV did not correlate with TCMR diagnosis. When combining the four glycolytic control proteins governing the phosphofructokinase-1 step of glycolysis (PFK-L, PFKFB2, PFKFB3 and PFKFB4), presence of ≥ 3 markers discriminated TCMR with ROC AUC of 0.73 (95% CI 0.50-0.96).
conclusionIncreased rate-limiting enzymes of glycolysis in UEV were detected in association with tubulointerstitial inflammation and fibrosis. This suggests altered energy metabolism in the form of increased renal glycolysis occurring in the tubular epithelium, consistent with findings in native kidney injury. Further work is required to evaluate whether this could serve as a non-invasive strategy to study pathology in kidney transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.